Laurent Christophe, Adam Jean-Philippe, Denost Quentin, Smith Denis, Saric Jean, Chiche Laurence
University of Bordeaux Segalen, 33076, Bordeaux, France.
Department of Hepatobiliary Surgery, CHU Bordeaux, Saint André Hospital, 1 rue Jean Burguet, 33075, Bordeaux, France.
World J Surg. 2016 May;40(5):1191-9. doi: 10.1007/s00268-016-3404-6.
The prognosis impact of positive margins after resection of colorectal liver metastases (CLM) in patients treated with modern effective chemotherapy has not been elucidated. The objective was to compare oncologic outcomes after R0 and R1 resections in the era of modern effective chemotherapy.
Between 1999 and 2010, all consecutive patients undergoing liver resection for CLM were analyzed retrospectively. Patients with extrahepatic metastases, macroscopic residual tumor, treated with combined radiofrequency, or not treated with chemotherapy were excluded. Survival and recurrence after R0 (tumor-free margin >0 mm) and R1 resections were analyzed.
Among 466 patients undergoing hepatectomy for CLM, 191 were eligible. Of them, 164 (86 %) received preoperative chemotherapy and 105 (55 %) received postoperative chemotherapy. R1 resection (10 %) was comparable in patients treated or not by preoperative chemotherapy. R1 status was associated with more intrahepatic recurrences. Overall survival (OS) (44 vs. 61 %; p = 0.047) and disease-free survival (DFS) (8 vs. 26 %; p = 0.082) were lower in patients after R1 compared to R0 resection (32 months of median follow-up). Preoperative chemotherapy and major hepatectomy were prognostic factors of survival, whereas postoperative chemotherapy was a protective factor from recurrences. In patients treated with preoperative chemotherapy, OS and DFS were similar between R1 and R0 resections (40 vs. 55 %, p = 0.104 and 9 vs. 22 %, p = 0.174, respectively).
In the era of modern effective chemotherapy, R1 resection leads to more intrahepatic recurrences but did not affect OS in selected patient responders to neoadjuvant chemotherapy. Postoperative chemotherapy protects from recurrences whatever the margin resection status.
现代有效化疗治疗的结直肠癌肝转移(CLM)患者切除术后切缘阳性对预后的影响尚未阐明。目的是比较现代有效化疗时代R0和R1切除术后的肿瘤学结局。
回顾性分析1999年至2010年间所有因CLM接受肝切除术的连续患者。排除有肝外转移、肉眼残留肿瘤、接受联合射频治疗或未接受化疗的患者。分析R0(切缘无肿瘤>0 mm)和R1切除术后的生存和复发情况。
在466例行CLM肝切除术的患者中,191例符合条件。其中,164例(86%)接受了术前化疗,105例(55%)接受了术后化疗。术前化疗与否的患者中R1切除率(10%)相当。R1状态与更多肝内复发相关。与R0切除术后患者相比,R1切除术后患者的总生存(OS)(44%对61%;p = 0.047)和无病生存(DFS)(8%对26%;p = 0.082)较低(中位随访32个月)。术前化疗和肝大部切除术是生存的预后因素,而术后化疗是预防复发的保护因素。在接受术前化疗的患者中,R1和R0切除术后的OS和DFS相似(分别为40%对55%,p = 0.104和9%对22%,p = 0.174)。
在现代有效化疗时代,R1切除导致更多肝内复发,但在新辅助化疗的部分反应患者中不影响OS。无论切缘切除状态如何,术后化疗均可预防复发。